Mitoxantrone Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Mitoxantrone Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
303
Registered trials
159
Result records
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Mitoxantrone Hydrochloride can convert its Small molecule drug profile and DNA x Top II biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Mitoxantrone Hydrochloride (query alias: mitoxantrone) |
|---|---|
| Modality / target | Small molecule drug; DNA x Top II; DNA inhibitors, Top II inhibitors |
| Highest global status | Approved |
| Originator | Merck Serono SA |
| Active developers | Shanghai Xidi Pharmaceutical Co. Ltd., Baxter Healthcare Pty Ltd., Fresenius Kabi Canada Ltd. |
The MCP disease footprint includes Acute Myeloid Leukemia, Locally advanced breast cancer, Metastatic breast cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600124493 | Phase 4 | Not yet recruiting | 30 | Objective Response Rate |
| NCT07525466 | Phase 1/2 | Recruiting | 25 | 6-month overall survival (OS) rate |
| NCT07389356 | Not Applicable | Not yet recruiting | 70 | Complete response rate (CRR) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
Phase 2; n=39; evaluation: not stated. Reported fields: Biochemical Response = 0 Participants ; -; -
Response to HiDAC/mitoxantrone/venetoclax (HMV) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).
Not Applicable; n=16; evaluation: Positive. Reported fields: Adverse ELN 2022 risk = 50.0 %
SAFETY AND EFFICACY OF MITOXANTRONE LIPOSOME COMBINED CHEMOTHERAPY IN THE TREATMENT OF MIXED PHENOTYPE ACUTE LEUKEMIA
Not Applicable; n=16; evaluation: Positive. Reported fields: AE = The main adverse effects were hematological toxicities. The incidence of agranulocytosis was 100%, the median duration time was 9 days (ranging from 2 to 18 days). The incidences of grade 4, grade 3, and grade 2 thrombocytopenia were 85.3%, 8.8%, and 5.9%, respectively. Only 4 cases (11.8%) of grade 3 transaminase elevation were observed, and no other obvious organ toxicity was observed.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Mitoxantrone Hydrochloride addresses Acute Myeloid Leukemia, Locally advanced breast cancer, Metastatic breast cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 0 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: DNA x Top II records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| No matched asset transaction returned. | |||
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition of KRAS G12C inhibitor and mitoxantrone and application thereof”. The milestone feed surfaced a patent-application signal described as “Use of pharmaceutical composition comprising mitoxantrone liposome and cytarabine in the treatment of acute myeloid leukemia”. The milestone feed surfaced a patent-application signal described as “Mitoxantrone hydrochloride ion pairing self-assembly nanoparticles as well as preparation method and application thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
